Specific completed treatment with Peg-interferon α2a (Pegasys) on 70% of patients gave the following results: Rapid virologic response (RVR): 71.4% (5/7), Early virologic response (EVR): 28.6% (2/7), Sustained virologic response (SVR): 85.71% (6/7).